PharmVar GeneFocus: CYP2C9

Katrin Sangkuhl, Karla Claudio-Campos, Larisa H. Cavallari, Jose A.G. Agundez, Michelle Whirl-Carrillo, Jorge Duconge, Andria L. Del Tredici, Mia Wadelius, Mariana Rodrigues Botton, Erica L. Woodahl, Stuart A. Scott, Teri E. Klein, Victoria M. Pratt, Ann K. Daly, Andrea Gaedigk

Research output: Contribution to journalReview articlepeer-review

Abstract

The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C9 gene. Genetic variation within the CYP2C9 gene locus impacts the metabolism or bioactivation of many clinically important drugs, including nonsteroidal anti-inflammatory drugs, phenytoin, antidiabetic agents, and angiotensin receptor blockers. Variable CYP2C9 activity is of particular importance regarding efficacy and safety of warfarin and siponimod as indicated in their package inserts. This GeneFocus provides a comprehensive overview and summary of CYP2C9 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase and the Clinical Pharmacogenetics Implementation Consortium.

Original languageEnglish
Pages (from-to)662-676
Number of pages15
JournalClinical Pharmacology and Therapeutics
Volume110
Issue number3
DOIs
StatePublished - Sep 2021

Fingerprint

Dive into the research topics of 'PharmVar GeneFocus: CYP2C9'. Together they form a unique fingerprint.

Cite this